STAT

NOVEMBER 18, 2023

The revolution started in silence. Jennifer Doudna and Emmanuelle Charpentier, now Nobelists , published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9. It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science.

145

145

The Guardian - Pharmaceutical Industry

NOVEMBER 18, 2023

Drug firm Novo Nordisk proposed singling out those most likely to return to work with its weight-loss injection Obesity jab maker Novo Nordisk suggested to senior government officials that they could “profile” benefit claimants so that those most likely to return to work could be targeted with its weight-loss injections. Internal documents obtained by the Observer reveal that Pinder Sahota, corporate vice-president of Novo Nordisk UK, told the then health secretary Steve Barclay, England’s chief

Documentation 111

Documentation 111

STAT

NOVEMBER 18, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay. “ The end of affirmative action means it’s time to revise pre-med requirements ,” by David Velasquez The ability to do well in both general and organic chemistry as well as physics that requires calculus are cours

97

97

Pharmaceutical Technology

NOVEMBER 18, 2023

Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.

40

40

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmaceutical Technology

NOVEMBER 18, 2023

TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-4157 is a mrna vaccine commercialized by Merck, with a leading Phase II program in Metastatic Melanoma.

Vaccines 40

Vaccines 40

Pharmaceutical Technology

NOVEMBER 18, 2023

Aflibercept Biosimilar. is a fusion protein commercialized by Celltrion, with a leading Phase III program in Diabetic Macular Edema.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-3705 is a gene therapy commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

RPA-501 is a gene therapy commercialized by Rocket Pharmaceuticals, with a leading Phase II program in Glycogen Storage Disorders (GSD).

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Aflibercept biosimilar is under clinical development by Amgen and currently in Phase III for Macular Edema.

40

40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

CMK-389 is under clinical development by Novartis and currently in Phase II for Pulmonary Sarcoidosis.

40

40